c-RET
Los inhibidores de c-RET se dirigen al protooncogén RET (Rearranged during Transfection), que codifica una tirosina quinasa receptora involucrada en el crecimiento, diferenciación y supervivencia celular. La activación anormal de la señalización de RET puede llevar a una proliferación celular descontrolada y resistencia a la apoptosis, contribuyendo al desarrollo de cánceres como el carcinoma medular de tiroides y el cáncer de pulmón de células no pequeñas. Inhibir c-RET puede inducir apoptosis en células cancerosas y es un enfoque prometedor en la terapia contra el cáncer dirigida. En CymitQuimica, ofrecemos una variedad de inhibidores de c-RET de alta calidad para apoyar su investigación en oncología, transducción de señales y apoptosis.
Se han encontrado 64 productos para "c-RET".
Filtrar por
Porcentaje de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Precio más bajo
- Precio más alto
- Pureza más baja
- Pureza más alta
- Entrega estimada más rápida
BT-13
CAS:BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.Fórmula:C23H27F4N3O4SPureza:99.23%Forma y color:SolidPeso molecular:517.537RET-IN-26
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].Forma y color:Odour SolidZeteletinib hemiadipate
CAS:Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Fórmula:C56H56F6N8O12Forma y color:SolidPeso molecular:1147.098QZ2135
QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.Fórmula:C53H54N12O4Forma y color:SolidPeso molecular:923.07RET-IN-28
CAS:RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.Fórmula:C26H29N9Forma y color:SolidPeso molecular:467.57ZW-18-116
ZW-18-116 (compound 9) is a dual-target PROTAC degrader focusing on the oncogenic proteins TRKA and RET. It induces the degradation of TRKA and RET by recruiting the CRBN E3 ligase. ZW-18-116 shows potent antiproliferative activity in various cancer cell lines harboring RET or TRKA fusion genes. This compound is applicable to research on RET or TRKA-related cancers such as thyroid, lung, and colon cancers.CDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Fórmula:C29H26N4OPeso molecular:446.21066RET ligand-3
RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.Fórmula:C38H42N10O3Forma y color:SolidPeso molecular:686.81RET-IN-4
CAS:RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.Fórmula:C27H31FN10O2Forma y color:SolidPeso molecular:546.611PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Fórmula:C22H22FN5O2Forma y color:SolidPeso molecular:407.44RET Ligand-Linker Conjugate-1
RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.Fórmula:C40H44N10OForma y color:SolidPeso molecular:680.84YW-N-7 TFA
YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.Fórmula:C58H63F3N12O9Forma y color:SolidPeso molecular:1129.19RET ligand-1
CAS:RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.Fórmula:C28H24F2N6O3Forma y color:SolidPeso molecular:530.525BT44
CAS:BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.Fórmula:C28H27F4N3O4SPureza:99.87%Forma y color:SolidPeso molecular:577.59Compound TPX-0046
CAS:Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.Fórmula:C21H21FN6O3Pureza:99.94%Forma y color:SoildPeso molecular:424.43AD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Fórmula:C22H21ClF3N7OPureza:98%Forma y color:SolidPeso molecular:491.9trans-Pralsetinib
CAS:trans-Pralsetinib (trans-BLU-667) is a RET inhibitor. It targets RET kinase to suppress tumor growth driven by RET mutations or rearrangements; used in lung and thyroid cancer research.Fórmula:C27H32FN9O2Pureza:98.06%Forma y color:Transparent ViscousPeso molecular:533.6Anti-Human c-RET Antibody
Anti-c-RET Antibody is a functional molecular tool targeting the c-RET proto-oncogene protein. Anti-c-RET Antibody demonstrates the capacity to identify the presence of the receptor in both malignant cell lineages and normal neural tissues and effectively facilitates the characterization of RET-mediated biological processes during designated laboratory testing procedures.Pureza:95%Pralsetinib
CAS:Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFórmula:C27H32FN9O2Pureza:97.88% - 99.89%Forma y color:White SolidPeso molecular:533.6005SPP-86
CAS:SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.Fórmula:C16H15N5Pureza:99.53%Forma y color:SolidPeso molecular:277.32
